INCY Incyte Corporation Stock Quote

INCY [NASD]

Index	S&P 500	P/E	49.73	EPS (ttm)	1.53	Insider Own	0.70%	Shs Outstand	220.08M	Perf Week	6.85%
Market Cap	17.15B	Forward P/E	17.10	EPS next Y	4.45	Insider Trans	-3.51%	Shs Float	217.55M	Perf Month	1.95%
Income	337.60M	PEG	2.38	EPS next Q	0.72	Inst Own	95.00%	Short Float	2.73%	Perf Quarter	-9.49%
Sales	2.72B	P/S	6.30	EPS this Y	-166.00%	Inst Trans	1.04%	Short Ratio	5.04	Perf Half Y	-4.26%
Book/sh	13.34	P/B	5.70	EPS next Y	45.55%	ROA	9.40%	Target Price	102.00	Perf Year	-15.96%
Cash/sh	9.22	P/C	8.24	EPS next 5Y	20.89%	ROE	12.70%	52W Range	70.97 - 101.47	Perf YTD	-12.64%
Dividend	-	P/FCF	38.12	EPS past 5Y	33.32%	ROI	-12.40%	52W High	-25.11%	Beta	0.78
Dividend %	-	Quick Ratio	3.90	Sales past 5Y	28.80%	Gross Margin	95.70%	52W Low	7.07%	ATR	1.72
Employees	1773	Current Ratio	4.00	Sales Q/Q	2.60%	Oper. Margin	15.00%	RSI (14)	54.18	Volatility	2.26% 2.20%
Optionable	Yes	Debt/Eq	0.01	EPS Q/Q	-48.90%	Profit Margin	12.40%	Rel Volume	2.14	Prev Close	75.04
Shortable	Yes	LT Debt/Eq	0.01	Earnings	Aug 03 BMO	Payout	0.00%	Avg Volume	1.18M	Price	75.99
Recom	2.20	SMA20	1.61%	SMA50	-0.50%	SMA200	-7.82%	Volume	2,520,202	Change	1.27%

Jul-20-21

Upgrade

The Benchmark Company

Hold → Buy

$89

Feb-10-21

Downgrade

SVB Leerink

Mkt Perform → Underperform

$70

Jan-07-21

Initiated

Truist

Buy

$120

Jan-04-21

Upgrade

Guggenheim

Neutral → Buy

Jun-16-20

Initiated

The Benchmark Company

Hold

May-06-20

Downgrade

JP Morgan

Overweight → Neutral

$89 → $99

Apr-29-20

Downgrade

Morgan Stanley

Overweight → Equal-Weight

$94

Apr-01-20

Upgrade

Morgan Stanley

Equal-Weight → Overweight

$83 → $90

Mar-24-20

Resumed

William Blair

Outperform

Mar-13-20

Upgrade

BofA/Merrill

Neutral → Buy

$83

Feb-04-20

Resumed

BofA/Merrill

Neutral

$82

Jan-03-20

Reiterated

BMO Capital Markets

Market Perform

$85 → $74

Jan-03-20

Downgrade

Mizuho

Buy → Neutral

$98 → $79

Jan-02-20

Downgrade

Guggenheim

Buy → Neutral

Oct-03-19

Initiated

Mizuho

Buy

$95

Sep-12-19

Initiated

BMO Capital Markets

Market Perform

Sep-05-19

Upgrade

Oppenheimer

Perform → Outperform

$100

Sep-05-19

Upgrade

JMP Securities

Mkt Perform → Mkt Outperform

$107

Sep-05-19

Resumed

Morgan Stanley

Equal-Weight

$82 → $87

May-21-19

Initiated

Credit Suisse

Neutral

$75

Sep-17-21 04:00PM	Incyte Announces Health Canada Conditional Approval of Pemazyre® (pemigatinib) as First Targeted Treatment for Adults with Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma CNW Group
Sep-13-21 04:30PM	Incyte Announces Ruxolitinib Cream Data Accepted for Presentation at the 2021 European Academy of Dermatology and Venereology (EADV) Virtual Congress Business Wire
Sep-02-21 11:31AM	Incyte (INCY) Down 0.4% Since Last Earnings Report: Can It Rebound? Zacks
08:34AM	FDA Hits JAK inhibitors With Heart Safety, Cancer Warnings: All You Need To Know Benzinga
Sep-01-21 10:44AM	Biotech Stock Roundup: REGN Gives Study Update, INCY Wins Drug Approval & More Zacks
Aug-27-21 11:09AM	Incyte (INCY), MorphoSys Win EC Approval for Lymphoma Drug Zacks
06:19AM	Incyte - MorphoSys's Diffuse Large B-Cell Lymphoma Drug Wins European Approval Benzinga
Aug-26-21 04:01PM	Incyte and MorphoSys Announce the European Commission Approval of Minjuvi® (tafasitamab) in Combination With Lenalidomide for the Treatment of Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Business Wire
Aug-24-21 08:30AM	Incyte Announces Health Canada Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma CNW Group
Aug-19-21 10:02AM	BriaCell, ImaginAb Join Forces To Assess Imaging Tech In Breast Cancer Trial Benzinga
Aug-17-21 08:28AM	The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business Benzinga
08:00AM	Incyte to Present at Upcoming Investor Conference Business Wire
06:37AM	Incyte Out Licenses Lymphoma Drug To InnoCare In Greater China Benzinga
Aug-16-21 07:00PM	Incyte and InnoCare Announce Collaboration and License Agreement for Tafasitamab in Greater China Business Wire
03:13PM	BriaCell Therapeutics Attacks Cancer with Novel Off-the-Shelf Immunotherapies Benzinga
Aug-10-21 02:49AM	Incyte (NASDAQ:INCY shareholders incur further losses as stock declines 4.0% this week, taking one-year losses to 20% Simply Wall St.
Aug-07-21 08:01AM	Is the PD-(L)1 Party Over After Incyte's FDA Rejection? Motley Fool
Aug-03-21 04:30PM	Incyte Corporation (INCY) Q2 2021 Earnings Call Transcript Motley Fool
12:43PM	Incyte (INCY) Q2 Earnings & Sales Beat on Solid Jakafi Growth Zacks
08:25AM	Incyte (INCY) Q2 Earnings and Revenues Beat Estimates Zacks
07:00AM	Incyte Reports 2021 Second Quarter Financial Results and Provides Updates on Key Clinical Programs Business Wire
06:31AM	UPDATE 1-Lilly's COVID-19 drug reduces death risk in patients on mechanical ventilation Reuters
06:00AM	Lilly and Incyte's baricitinib reduced deaths among patients with COVID-19 receiving invasive mechanical ventilation PR Newswire
Aug-02-21 09:36AM	Drug/Biotech Stock Q2 Earnings on Aug 3: LLY, AMGN & More Zacks
Jul-31-21 08:38AM	2 Stocks Under $100 You Can Buy and Hold Forever Motley Fool
Jul-28-21 01:51PM	Biotech Stock Roundup: BIIB's Q2 Earnings Update & Other Updates From AMGN, INCY Zacks
09:59AM	Incyte (INCY) to Post Q2 Earnings: Will Jakafi Sales Disappoint? Zacks
Jul-27-21 03:03PM	Earnings Preview: Incyte (INCY) Q2 Earnings Expected to Decline Zacks
Jul-23-21 04:30PM	Incyte Provides Regulatory Update on Retifanlimab for the Treatment of Certain Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Business Wire
Jul-22-21 11:40AM	REGN or INCY: Which Is the Better Value Stock Right Now? Zacks
Jul-19-21 11:16AM	AbbVie (ABBV) Rinvoq Dermatitis' sNDA Decision Delayed by FDA Zacks
10:31AM	Lilly (LLY), Incyte's Decision on Olumiant sNDA Delayed by FDA Zacks
Jul-16-21 01:57PM	AbbVie, Lilly Atopic Dermatitis Treatments Hit With Further Delays With FDA Benzinga
Jul-15-21 08:00AM	Incyte to Report Second Quarter Financial Results Business Wire
07:56AM	Theratechnologies In Search Of Potential Partner For Late-Stage NASH Study Of Tesamorelin, Reports Q2 Earnings Benzinga
07:12AM	Incyte's Ruxolitinib Shows Better Outcomes Regardless Of Organs Affected In GvHD Patients Benzinga
Jul-14-21 05:00PM	Incyte Announces Positive Phase 3 REACH3 Study Data Published in NEJM for Ruxolitinib (Jakafi®) in Chronic Graft-Versus-Host Disease Business Wire
Jul-09-21 09:47AM	Innovent Biologics - Incyte's Pemigatinib Application Under Review In China For Bile Duct Cancer Benzinga
Jul-06-21 12:43AM	Hedge Funds Are Selling Incyte Corporation (INCY) Insider Monkey
Jun-28-21 01:18PM	Incyte's (INCY) Lymphoma Drug Obtains Positive CHMP Opinion Zacks
11:40AM	REGN vs. INCY: Which Stock Is the Better Value Option? Zacks
Jun-25-21 07:42AM	Incyte and MorphoSys Announce Positive CHMP Opinion for Tafasitamab in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Business Wire
Jun-24-21 03:30PM	Incyte Announces Outcome of FDA Oncologic Drugs Advisory Committee (ODAC) Meeting Reviewing Retifanlimab as a Treatment for Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Business Wire
Jun-20-21 05:11AM	How This Pharma Company Can Benefit From Its Competitors Motley Fool
Jun-14-21 10:34AM	Incyte (INCY) Faces Delay in Approval of Atopic Dermatitis Cream Zacks
Jun-12-21 05:01PM	Incyte Announces Updated Data for Ruxolitinib Cream Accepted for Presentation at the 2021 Revolutionizing Atopic Dermatitis (RAD) Virtual Conference Business Wire
Jun-11-21 11:40AM	REGN vs. INCY: Which Stock Should Value Investors Buy Now? Zacks -5.66%
10:53AM	Incyte Sees Delay in FDA Review of Eczema Cream TheStreet.com
07:30AM	Incyte Announces U.S. FDA Has Extended the New Drug Application Review Period for Ruxolitinib Cream for the Treatment of Atopic Dermatitis Business Wire
Jun-09-21 04:00PM	Incyte's (INCY) sNDA Review for Jakafi in GVHD Gets Extended Zacks
03:53PM	Biotech Stock Roundup: BIIB's Drug Approval, ALXN Drug Label Expansion & More Zacks
Jun-08-21 07:30AM	Incyte Announces U.S. FDA Has Extended the sNDA Review Period for Ruxolitinib (Jakafi®) in Chronic Graft-Versus-Host Disease (GVHD) Business Wire
Jun-04-21 02:00PM	MorphoSys and Incyte Announce Three-Year Results from Phase 2 L-MIND Study of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory DLBCL ACCESSWIRE
01:45PM	Incyte and MorphoSys Announce Three-Year Results from Phase 2 L-MIND Study of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory DLBCL Business Wire
Jun-03-21 11:31AM	Incyte (INCY) Up 1.2% Since Last Earnings Report: Can It Continue? Zacks
Jun-02-21 12:06PM	Lilly's Olumiant Found to Lower Pain In Late-Stage Rheumatoid Arthritis Trial Benzinga
Jun-01-21 07:30PM	OLUMIANT® Improved Pain, Physical Function and Morning Joint Stiffness in Rheumatoid Arthritis in Phase 3 Post-Hoc Analyses PR Newswire
May-20-21 08:00AM	Incyte to Present at Upcoming Investor Conferences Business Wire
06:00AM	Positive Primary Analysis from the Phase 2 OPTIC Study of Ponatinib (Iclusig®) in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) to be Presented at the 2021 ASCO Annual Meeting Business Wire
May-19-21 05:14PM	Data from Incytes Oncology Portfolio Accepted for Presentation at the 2021 ASCO Annual Meeting Business Wire
May-18-21 05:07PM	Incyte (INCY) Announces Positive Results From Vitiligo Study Zacks
May-17-21 12:36PM	Incyte's Ruxolitinib Cream Aces Late-Stage Vitiligo Trials, Teeing Up Regulatory Submissions Benzinga
07:30AM	Incyte Announces Positive Results from Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream in Patients with Vitiligo Business Wire
May-12-21 04:18PM	Data From Incytes Oncology Portfolio Accepted for Presentation at the 2021 EHA Virtual Congress Business Wire
03:47AM	Should Weakness in Incyte Corporation's (NASDAQ:INCY) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials? Simply Wall St.
May-11-21 04:01PM	Incyte and MorphoSys Announce First Patient Dosed in Phase 3 frontMIND Study Evaluating Tafasitamab Combination as a First-Line Treatment for Diffuse Large B-Cell Lymphoma Business Wire
May-04-21 01:47PM	Incyte (INCY) Q1 Earnings Beat, Sales Miss on Soft Jakafi Zacks -5.25%
12:30PM	Incyte Corp (INCY) Q1 2021 Earnings Call Transcript Motley Fool
08:25AM	Incyte (INCY) Tops Q1 Earnings Estimates Zacks
07:00AM	Incyte Reports 2021 First Quarter Financial Results and Provides Updates on Key Clinical Programs Business Wire
06:15AM	Incyte Corp. to Host Earnings Call ACCESSWIRE
May-03-21 08:00AM	Incyte Announces Data on Ruxolitinib Cream in Atopic Dermatitis Accepted for Presentation at the Society for Investigative Dermatology (SID) Virtual Meeting 2021 Business Wire
07:54AM	Is a Surprise Coming for Incyte (INCY) This Earnings Season? Zacks
Apr-27-21 08:00AM	Incyte to Present at Upcoming Investor Conference Business Wire
Apr-26-21 11:41AM	Will Jakafi's Performance Fuel Incyte's (INCY) Q1 Earnings? Zacks
Apr-23-21 01:20PM	Incyte Announces New Ruxolitinib Data From Atopic Dermatitis and Vitiligo Studies Benzinga
10:01AM	OLUMIANT® Showed Significant Improvements in the Severity and Extent of Atopic Dermatitis and Other Patient-Reported Outcomes in Phase 3 Study Analyses PR Newswire
10:00AM	Incyte Announces New Findings from Pooled Analyses of the Phase 3 TRuE-AD Program Evaluating Ruxolitinib Cream in Patients with Atopic Dermatitis Business Wire
10:00AM	Incyte Announces New Findings from a Randomized Phase 2 Study of Ruxolitinib Cream in Patients with Vitiligo Business Wire
Apr-21-21 02:54PM	Biotech Stock Roundup: BMYs Opdivo Gets FDA Nod for Gastric Cancer & Other Updates Zacks
12:23PM	Regeneron and 4 More Biopharma Stocks That Look Cheap Barrons.com
Apr-20-21 09:46AM	Incyte (INCY), MorphoSys Initiate Dosing in Lymphoma Study Zacks
08:00AM	Multiple Abstracts from Incytes Dermatology Portfolio Accepted for Presentation at the AAD Virtual Meeting Experience Business Wire
06:45AM	Lilly and Incyte's Baricitinib Improved Hair Regrowth for Alopecia Areata Patients in Second Phase 3 Study PR Newswire
Apr-19-21 04:01PM	Incyte and MorphoSys Announce First Patient Dosed in Phase 3 inMIND Study Evaluating the Addition of Tafasitamab to Lenalidomide and Rituximab in Relapsed or Refractory Follicular or Marginal Zone Lymphoma Business Wire
10:24AM	Eli Lilly And Incytes Baricitinib Fails To Meet Endpoint In Phase 3 COVID-19 Trial SmarterAnalyst
Apr-13-21 08:00AM	Incyte to Report First Quarter Financial Results Business Wire
Apr-09-21 09:55AM	Lilly's (LLY) JAK Inhibitor Olumiant Fails COVID-19 Study Zacks
Apr-08-21 07:41AM	Eli Lilly-Incyte's Baricitinib Study In Hospitalized COVID-19 Patients Fails To Meet Main Goal Benzinga
07:01AM	Eli Lilly and Incyte say Phase 3 study of baricitinib in hospitalized COVID-19 patients failed to meet main goal MarketWatch
06:45AM	Lilly and Incyte announce results from the Phase 3 COV-BARRIER study of baricitinib in hospitalized COVID-19 patients PR Newswire
Apr-07-21 05:26PM	Is INCY Stock A Buy or Sell? Insider Monkey
Apr-06-21 04:30PM	Lilly and Incyte communicate review extension of supplemental New Drug Application for baricitinib for the treatment of moderate to severe atopic dermatitis PR Newswire
Mar-31-21 01:33PM	Biotech Stock Roundup: BLUE/BMY's CAR T Therapy Nod, KLDO's COVID-19 Study News & More Zacks
Mar-30-21 10:06AM	Incyte (INCY) Gets EU Nod for Cholangiocarcinoma Drug Pemazyre Zacks
Mar-29-21 02:34PM	Incyte's Pemazyre Wins European Approval For Bile Duct Cancer Benzinga
12:04PM	Incyte Announces the European Commission Approval of Pemazyre® (pemigatinib) as a Treatment for Adults with Locally Advanced or Metastatic Cholangiocarcinoma with a Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion or Rearrangement Business Wire
Mar-24-21 03:43PM	Biotech Stock Roundup: REGN Cocktail Data Positive, INCY's Jakafi Disappoints & More Zacks
Mar-23-21 05:13AM	Incyte Announces Approval of Pemazyre® (pemigatinib) in Japan for the Treatment of Patients with Unresectable Biliary Tract Cancer (BTC) with a Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene, Worsening After Cancer Chemotherapy Business Wire
Mar-19-21 09:40AM	Incyte's Jakafi failed Phase 3 clinical trial as a treatment for some severely ill COVID-19 patients MarketWatch

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor for the treatment of adults; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug that is in Phase III clinical trial for steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase III clinical trial to treat naive chronic GVHD; and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, 8p11 myeloproliferative syndrome, and Tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, the company develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; and Cellenkos, Inc., as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Dhanak Dashyant	EVP & Chief Scientific Officer	Sep 01	Sale	76.71	388	29,763	31,652	Sep 03 07:40 AM
Dhanak Dashyant	EVP & Chief Scientific Officer	Aug 02	Sale	77.49	389	30,144	32,040	Aug 04 04:16 PM
Iyengar Vijay K	EVP GPS, BD, & Licensing	Jul 29	Sale	78.29	4,911	384,482	27,005	Aug 02 04:14 PM
Wenqing Yao	EVP, Head of Discovery Chem	Jun 29	Sale	85.37	27,194	2,321,552	94,080	Jun 30 04:11 PM
Pasquale Maria E	EVP & General Counsel	Jun 18	Option Exercise	65.36	255	16,667	30,193	Jun 22 04:04 PM
Dhanak Dashyant	EVP & Chief Scientific Officer	Jun 10	Option Exercise	65.42	3,845	251,540	30,390	Jun 14 04:28 PM
Dhanak Dashyant	EVP & Chief Scientific Officer	Jun 10	Sale	87.00	3,845	334,515	26,545	Jun 14 04:28 PM
Dhanak Dashyant	EVP & Chief Scientific Officer	Jun 01	Sale	84.13	395	33,231	26,545	Jun 03 04:42 PM
BAKER BROS. ADVISORS LP	Director	May 14	Option Exercise	18.97	40,000	758,800	29,334,516	May 18 04:25 PM
Pasquale Maria E	EVP & General Counsel	Apr 23	Option Exercise	65.36	127	8,301	29,938	Apr 27 04:57 PM
Dhanak Dashyant	EVP & Chief Scientific Officer	Apr 01	Sale	81.57	396	32,302	27,336	Apr 05 04:25 PM
Morrissey Michael James	EVP, Head of Tech. Operations	Mar 29	Sale	81.08	20,000	1,621,600	45,452	Mar 31 04:10 PM
Pasquale Maria E	EVP & General Counsel	Mar 12	Option Exercise	65.36	128	8,366	30,328	Mar 16 04:17 PM
Dhanak Dashyant	EVP & Chief Scientific Officer	Mar 01	Sale	79.73	395	31,493	27,732	Mar 03 04:28 PM
Hoppenot Herve	Chairman / CEO	Feb 23	Buy	77.37	12,925	1,000,007	284,231	Feb 23 04:54 PM
Pasquale Maria E	EVP & General Counsel	Feb 16	Option Exercise	65.36	127	8,301	30,200	Feb 18 04:38 PM
Dhanak Dashyant	EVP & Chief Scientific Officer	Feb 01	Option Exercise	65.42	961	62,869	29,483	Feb 03 04:27 PM
Dhanak Dashyant	EVP & Chief Scientific Officer	Feb 01	Sale	90.00	1,356	122,040	28,127	Feb 03 04:27 PM
Iyengar Vijay K	EVP GPS, BD, & Licensing	Jan 25	Option Exercise	72.86	4,116	299,892	31,274	Jan 27 05:03 PM
Wenqing Yao	EVP, Head of Discovery Chem	Jan 25	Option Exercise	73.21	21,545	1,577,309	163,770	Jan 27 05:32 PM
Stein Steven H	EVP & Chief Medical Officer	Jan 25	Option Exercise	68.62	3,795	260,413	123,539	Jan 27 05:09 PM
Wenqing Yao	EVP, Head of Discovery Chem	Jan 25	Sale	100.00	21,545	2,154,500	143,784	Jan 27 05:32 PM
Iyengar Vijay K	EVP GPS, BD, & Licensing	Jan 25	Sale	99.00	5,116	506,484	26,158	Jan 27 05:03 PM
Stein Steven H	EVP & Chief Medical Officer	Jan 25	Sale	100.00	3,795	379,500	119,744	Jan 27 05:09 PM
Flannelly Barry P	EVP & General Manager US	Jan 25	Sale	100.00	2,744	274,400	49,994	Jan 27 04:52 PM
Pasquale Maria E	EVP & General Counsel	Jan 11	Option Exercise	65.36	127	8,301	30,073	Jan 13 04:15 PM
Pasquale Maria E	EVP & General Counsel	Dec 11	Option Exercise	65.36	128	8,366	29,946	Dec 15 04:51 PM
Pasquale Maria E	EVP & General Counsel	Nov 12	Option Exercise	65.36	127	8,301	28,586	Nov 16 04:56 PM
BIENAIME JEAN JACQUES	Director	Nov 10	Sale	83.00	798	66,234	8,646	Nov 12 04:41 PM
Dhanak Dashyant	EVP & Chief Scientific Officer	Nov 06	Option Exercise	65.42	961	62,869	28,971	Nov 10 04:26 PM
Dhanak Dashyant	EVP & Chief Scientific Officer	Nov 06	Sale	85.17	961	81,848	28,010	Nov 10 04:26 PM
Flannelly Barry P	EVP & General Manager US	Nov 02	Option Exercise	48.44	20,000	968,800	59,984	Nov 04 04:15 PM
Flannelly Barry P	EVP & General Manager US	Nov 02	Sale	86.60	20,000	1,732,000	39,984	Nov 04 04:15 PM
Pasquale Maria E	EVP & General Counsel	Oct 12	Option Exercise	65.36	128	8,366	28,459	Oct 13 05:10 PM
Pasquale Maria E	EVP & General Counsel	Oct 09	Option Exercise	68.62	1,423	97,646	29,754	Oct 13 05:10 PM
Pasquale Maria E	EVP & General Counsel	Oct 09	Sale	95.00	1,423	135,185	28,331	Oct 13 05:10 PM
Dhanak Dashyant	EVP & Chief Scientific Officer	Oct 06	Option Exercise	65.42	961	62,869	28,971	Oct 08 04:21 PM
Dhanak Dashyant	EVP & Chief Scientific Officer	Oct 06	Sale	91.97	961	88,383	28,010	Oct 08 04:21 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience